Assessing Cumulative, Meaningful Benefits of Disease-Modifying Therapies Targeting Synucleinopathies: Conference...

Area of Science:

• Neuroscience
• Pharmacology
• Patient Advocacy

Background:

• Synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, are a group of neurodegenerative disorders characterized by shared pathobiology and clinical features.
• Current treatments for synucleinopathies primarily offer symptomatic relief, while disease-modifying therapies (DMTs) targeting underlying disease processes are under development.
• Regulatory approval of DMTs may be forthcoming, but patient access depends on broader considerations of meaningful benefit beyond safety and efficacy.

Purpose of the Study:

• To summarize the key discussions and outcomes of the Workshop on Assessing Cumulative Benefits of Disease-Modifying Therapies (DMTs) Targeting Synucleinopathies.
• To foster collaboration among academia, industry, and patient advocacy groups to define and prioritize the cumulative benefits of DMTs for synucleinopathies.
• To explore the multifaceted perspectives on 'meaningful benefit' from various stakeholders, including patients, clinicians, payers, and regulators.

Main Methods:

• A workshop was convened involving diverse stakeholders: academic researchers, industry representatives, patient advocacy groups, clinicians, payers, and government representatives.
• Discussions focused on defining and assessing the cumulative benefits of emerging DMTs for synucleinopathies.
• Key themes included differing stakeholder perspectives on benefit, patient access, and future research priorities.

Main Results:

• Identified a critical need to align diverse stakeholder definitions of 'meaningful benefit' for DMTs in synucleinopathies.
• Highlighted the gap between regulatory standards (safety, efficacy) and patient/clinician-centric views of benefit.
• Emphasized the importance of collaboration to ensure patient access to novel therapies.

Conclusions:

• Achieving meaningful patient benefit from DMTs for synucleinopathies requires a comprehensive understanding that extends beyond clinical trial endpoints.
• Addressing the varied perspectives on benefit across patient, clinician, payer, and regulatory bodies is crucial for successful therapy adoption.
• Continued dialogue and collaboration among all stakeholders are essential to navigate the path toward improved outcomes for individuals with synucleinopathies.